These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30691369)

  • 1. New Drugs in Multiple Myeloma.
    Kunacheewa C; Orlowski RZ
    Annu Rev Med; 2019 Jan; 70():521-547. PubMed ID: 30691369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
    Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
    Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How I manage the toxicities of myeloma drugs.
    Delforge M; Ludwig H
    Blood; 2017 Apr; 129(17):2359-2367. PubMed ID: 28275090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapies for multiple myeloma.
    Wallington-Beddoe CT; Pitson SM
    Aging (Albany NY); 2017 Aug; 9(8):1857-1858. PubMed ID: 28854147
    [No Abstract]   [Full Text] [Related]  

  • 5. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
    Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
    Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.
    Kazandjian D; Landgren O
    Semin Oncol; 2016 Dec; 43(6):682-689. PubMed ID: 28061986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapies in multiple myeloma.
    El-Amm J; Tabbara IA
    Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibitors for multiple myeloma.
    Okazuka K; Ishida T
    Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
    Ashjian E; Redic K
    J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
    Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
    Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update in treatment options for multiple myeloma in nontransplant eligible patients.
    Broijl A; Sonneveld P
    Expert Opin Pharmacother; 2015; 16(13):1945-57. PubMed ID: 26245702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapies in monoclonal gammopathies.
    Niesvizky R
    Hematology; 2012 Apr; 17 Suppl 1():S121-4. PubMed ID: 22507798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel targeted therapy in multiple myeloma].
    Izumi T
    Nihon Rinsho; 2014 Jun; 72(6):1089-93. PubMed ID: 25016809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma : recent progress in diagnosis and treatment.
    Chou T
    J Clin Exp Hematop; 2012; 52(3):149-59. PubMed ID: 23269074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elotuzumab as a novel anti-myeloma immunotherapy.
    Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Not Available].
    Hitz F
    Praxis (Bern 1994); 2016; 105(21):1255-1260. PubMed ID: 28573955
    [No Abstract]   [Full Text] [Related]  

  • 18. New pharmacotherapy options for multiple myeloma.
    Mina R; Cerrato C; Bernardini A; Aghemo E; Palumbo A
    Expert Opin Pharmacother; 2016; 17(2):181-92. PubMed ID: 26684262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage therapy of multiple myeloma: the new generation drugs.
    Romano A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Di Martina V; Schinocca E; La Fauci A; Parrinello NL; Chiarenza A; Di Raimondo F
    Biomed Res Int; 2014; 2014():456037. PubMed ID: 24967371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
    Varga C; Laubach JP; Anderson KC; Richardson PG
    Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.